Recursion Pharmaceuticals (RXRX) Share-based Compensation (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 6 years of Share-based Compensation data on file, last reported at $22.2 million in Q1 2026.

• Quarterly Share-based Compensation fell 38.39% year-over-year to $22.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.4 million (down 85.02% YoY) and the FY2025 annual result came in at $111.2 million, down 82.35% from the prior year.
• Share-based Compensation declined to $22.2 million in Q1 2026, from $90.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $630.1 million in Q4 2024 to a low of -$41.9 million in Q3 2025.
• A 5-year average of $48.1 million and a median of $16.1 million in 2023 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 3817.22% in 2024, down 294.44% in 2024.
• Tracing RXRX's Share-based Compensation over 5 years: stood at -$4.0 million in 2022, then soared by 507.24% to $16.1 million in 2023, then soared by 3817.22% to $630.1 million in 2024, then plunged by 85.57% to $90.9 million in 2025, then plunged by 75.56% to $22.2 million in 2026.
• The last three Share-based Compensation figures came in at $22.2 million (Q1 2026), $90.9 million (Q4 2025), and -$41.9 million (Q3 2025), per Business Quant data.